Capital Asset Advisory Services’s West Pharmaceutical WST Stock Holding History

Capital Asset Advisory Services’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-831	Closed	-$251K	–	592
2022 Q2	$251K	Buy	831 +90	+12%	+$29.3K	0.03%	342
2022 Q1	$304K	Buy	741 +208	+39%	+$81.4K	0.03%	327
2021 Q4	$250K	Sell	533 -19	-3%	-$8.18K	0.03%	352
2021 Q3	$234K	Sell	552 -14	-2%	-$5.9K	0.03%	388
2021 Q2	$203K	Buy	+566	New	+$187K	0.02%	428
2021 Q1	–	Sell	-307	Closed	-$87K	–	1514
2020 Q4	$87K	Buy	+307	New	+$86.1K	0.02%	490

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Asset Advisory Services's WST Position: Q3 2022 in Review

Capital Asset Advisory Services sold out of West Pharmaceutical (WST) in Q3 2022, closing a stake of 831 shares — an estimated $251K sold.

Capital Asset Advisory Services first reported a position in WST in Q4 2020 and held it in 6 quarters. The position peaked at $304K in Q1 2022. 637 funds tracked by Wall St. Rank hold WST as of Q3 2022.

Capital Asset Advisory Services reported no remaining West Pharmaceutical position as of Q3 2022 after selling out during the quarter.
Capital Asset Advisory Services sold 831 West Pharmaceutical shares in Q3 2022, an estimated $251K.
Capital Asset Advisory Services first reported a position in West Pharmaceutical in Q4 2020 and held it in 6 quarters.
Capital Asset Advisory Services's West Pharmaceutical position peaked at $304K in Q1 2022.
637 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2022.

Based on Capital Asset Advisory Services's 13F filing for Q3 2022, filed 14 Nov 2022.